NASDAQ$NEOG
Neogen Corporation · Q2 2024 earnings
Q2 2024 earnings · · Investor relations
Briefing
Neogen's Q2 2024 results were announced, revealing a slight decrease in revenue but progress in integrating the former 3M Food Safety business.
Neogen Corporation reported Q2 2024 revenue of $229.6 million, a slight decrease of 0.2% year-over-year. The company experienced a net loss of $3.5 million, or $(0.02) per diluted share, but an adjusted net income of $24.9 million, or $0.11 per diluted share. The results reflect ongoing integration efforts and stabilization in end markets, with an updated full-year outlook provided.
- Revenue reached $229.6 million, slightly down by 0.2% compared to the previous year.
- Net loss amounted to $3.5 million, or $(0.02) per diluted share.
- Adjusted net income was $24.9 million, or $0.11 per diluted share.
- The company is updating its full-year outlook, anticipating slower improvements in end markets.
Headline financials
Revenue & EPS history
Neogen · Revenue · Quarterly
$230M
Revenue by segment
Neogen · $229M total across 2 segments · Q1 2024
- Food Safety$166M+157.3%72.6%
- Animal Safety$62.7M-7.4%27.4%
Forward guidance
Neogen is updating its full-year outlook, expecting revenue to be in the range of $935 million to $955 million, with Adjusted EBITDA in the range of $230 million to $240 million. Capital expenditures are still expected to be approximately $130 million, including approximately $100 million related specifically to the integration of the former 3M Food Safety Division. Improvements in its primary end markets are likely to happen at a slower pace than originally anticipated.
Tailwinds
- Integration of the former 3M Food Safety business is progressing with notable milestones achieved.
- Order flows in the Food Safety segment have remained stable, indicating core growth.
- Solid core growth was observed in Petrifilm, with accelerated growth in Asia.
- Destocking by distributors in the Animal Safety segment is moderating.
- Inflation appears to be easing, potentially leading to increased food production volumes.
Headwinds
- Improvements in end markets are expected to happen at a slower pace than originally anticipated.
- The strategic shift in focus of the Genomics business is creating incremental headwinds.
- Destocking by distributors in the Animal Safety segment continued.
- The domestic Genomics business experienced a decline due to customer attrition.
- The Animal Care & Other product category experienced a core revenue decline due largely to lower sales of small-animal supplements and wound-care products.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2024
-1.4%
Avg return
Earnings day
-2.4%
Avg return
5 days after
-1.8%
Avg return
30 days after
36%
23 / 64 earnings
Positive
+31.5%
Q2 2026
Best reaction
-28.7%
Q3 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q3 2026 | +3.9% | -7.1% | -12.5% | |
| Q2 2026 | +31.5% | +24.5% | +46.3% | |
| Q1 2026 | +16.4% | +1.5% | +10.0% | |
| Q3 2025 | -28.7% | -23.3% | -15.2% | |
| Q2 2025 | -3.3% | -13.1% | -20.7% | |
| Q1 2025 | -2.8% | -0.8% | +9.3% | |
| Q4 2024 | -1.6% | -5.3% | -1.0% | |
| Q3 2024 | -13.1% | -13.9% | -13.6% | |
| Q2 2024 | -5.5% | -8.4% | -18.0% | |
| Q1 2024 | -11.7% | -8.8% | -11.0% | |
| Q4 2023 | +2.3% | +0.0% | +0.8% | |
| Q3 2023 | +0.2% | -3.6% | -6.9% | |
| Q2 2023 | +5.1% | +11.2% | +30.3% | |
| Q1 2023 | -1.0% | -4.1% | -12.2% | |
| Q4 2022 | +8.0% | +7.5% | -2.8% | |
| Q3 2022 | -7.4% | -5.3% | -15.3% | |
| Q2 2022 | +1.4% | +0.2% | -19.2% | |
| Q1 2022 | +3.0% | +6.1% | +2.9% | |
| Q4 2021 | +0.2% | -1.9% | -3.6% | |
| Q3 2021 | +3.0% | +5.6% | +14.9% | |
| Q2 2021 | +1.2% | +0.5% | +3.8% | |
| Q1 2021 | +0.2% | +1.1% | -4.3% | |
| Q4 2020 | -4.0% | -4.0% | -2.9% | |
| Q3 2020 | -5.3% | -1.2% | +8.1% | |
| Q2 2020 | -5.4% | -5.7% | +1.2% | |
| Q1 2020 | -10.6% | -13.0% | -13.1% | |
| Q4 2019 | +9.0% | +10.6% | +13.2% | |
| Q3 2019 | -8.3% | -5.2% | -4.4% | |
| Q2 2019 | -8.1% | -10.7% | +2.4% | |
| Q1 2019 | -17.8% | -19.3% | -30.4% | |
| Q4 2018 | +1.5% | +1.7% | +3.9% | |
| Q3 2018 | -4.2% | +1.0% | +7.6% | |
| Q2 2018 | -0.8% | -0.7% | -1.8% | |
| Q1 2018 | -4.4% | -1.5% | +6.4% | |
| Q4 2017 | -2.2% | -1.8% | -4.5% | |
| Q3 2017 | -5.9% | -6.7% | -9.8% | |
| Q2 2017 | +3.8% | +5.6% | +0.5% | |
| Q1 2017 | -4.7% | -2.8% | -10.1% | |
| Q4 2016 | -1.6% | -1.8% | -0.4% | |
| Q3 2016 | -14.6% | — | — | |
| Q2 2016 | -2.0% | — | — | |
| Q1 2016 | -12.1% | — | — | |
| Q4 2015 | +25.2% | — | — | |
| Q3 2015 | -3.4% | — | — | |
| Q2 2015 | +1.2% | — | — | |
| Q1 2015 | -1.7% | — | — | |
| Q4 2014 | +11.3% | — | — | |
| Q3 2014 | -0.1% | — | — | |
| Q2 2014 | -5.6% | — | — | |
| Q1 2014 | -0.3% | — | — | |
| Q4 2013 | -4.9% | — | — | |
| Q3 2013 | +0.5% | — | — | |
| Q2 2013 | -0.7% | — | — | |
| Q1 2013 | +7.5% | — | — | |
| Q4 2010 | -2.9% | — | — | |
| Q4 2012 | -2.9% | — | — | |
| Q3 2012 | -0.3% | — | — | |
| Q3 2011 | -0.3% | — | — | |
| Q2 2011 | +2.5% | — | — | |
| Q2 2012 | +2.5% | — | — | |
| Q4 2011 | -7.3% | — | — | |
| Q1 2011 | -7.3% | — | — | |
| Q1 2012 | -7.3% | — | — | |
| Q3 2010 | -0.5% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro